ストックスクリーナーアプリを入手
0.66
0.92%
0.006
アフターアワーズ：
.66
前日終値:
$0.654
開ける：
$0.6488
24時間の取引高:
3.16M
Relative Volume:
5.47
時価総額：
$40.77M
収益：
-
当期純損益:
$-68.80M
株価収益率:
-0.322
EPS:
-2.05
ネットキャッシュフロー:
$-59.06M
1週間 パフォーマンス:
-13.04%
1か月 パフォーマンス:
+28.48%
6か月 パフォーマンス:
-29.03%
1年 パフォーマンス:
-19.00%
1日の値動き範囲:
$0.60
$0.72
1週間の範囲:
$0.60
$0.7525
52週間の値動き範囲:
$0.451
$1.79
Passage Bio Inc Stock (PASG) Company Profile
名前
Passage Bio Inc
セクター
電話
(267) 866-0312
住所
ONE COMMERCE SQUARE, PHILADELPHIA, PA
PASG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.66 | 40.77M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-29 | 再開されました | Wedbush | Outperform |
| 2024-09-03 | 開始されました | Rodman & Renshaw | Buy |
| 2022-03-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-19 | ダウングレード | Goldman | Buy → Neutral |
| 2021-07-01 | 開始されました | Raymond James | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-03-04 | アップグレード | Goldman | Neutral → Buy |
| 2021-02-04 | 開始されました | Guggenheim | Buy |
| 2021-01-25 | 開始されました | Wedbush | Outperform |
| 2021-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 開始されました | Citigroup | Neutral |
| 2020-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-25 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2020-03-24 | 開始されました | Cowen | Outperform |
| 2020-03-24 | 開始されました | Goldman | Buy |
| 2020-03-24 | 開始されました | JP Morgan | Overweight |
すべてを表示
Passage Bio Inc (PASG) 最新ニュース
Orbimed advisors sells $51,988 in Passage Bio shares By Investing.com - Investing.com South Africa
Orbimed advisors sells $51,988 in Passage Bio shares - Investing.com India
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
WuXi Firms Surge on Slimmer Chances of US Biosecure Passage | Stock Market News - Mint
WuXi Firms Surge on Slimmer Chances of US Biosecure Passage - Yahoo Finance
ORBIMED ADVISORS LLC Reduces Holdings in Passage Bio Inc - GuruFocus.com
Orbimed advisors sells Passage Bio shares worth $77,338 By Investing.com - Investing.com Australia
Orbimed advisors sells Passage Bio shares worth $77,338 - Investing.com
Erste Asset Management GmbH Takes Position in Passage Bio, Inc. (NASDAQ:PASG) - MarketBeat
Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology - Financial Times
Layoff Tracker: Agenus to Lay Off Staff as Part of Cost-Cutting Moves - BioSpace
Passage Bio assumed with an Outperform at Wedbush - Yahoo Finance
Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR
Passage Bio sees $284,519 in stock purchases by Lynx1 Capital - Investing.com South Africa
Insider Activity Roundup: Wednesday's Top Buys and Sells Revealed By Investing.com - Investing.com Canada
Insider Activity Roundup: Wednesday's Top Buys and Sells Revealed - Investing.com
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus.com
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MSN
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOn November 13, 2024, Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary dise - Defense World
Horizon Space Acquisition I Corp. Approved for Listing on Nasdaq Capital Market - Defense World
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
Metal Sky Star Acquisition Amends Investment Management Trust Agreement and Extends Business Combination Period - Defense World
Nikola Corporation Enters Material Definitive Agreements, Modifies Convertible Notes – 8-K Filing Highlights - Defense World
Air Industries Group to Release Financial Results for Q3 2024 - Defense World
AgriFORCE Growing Systems Announces Strategic Shift Towards Sustainable Technology Initiatives - Defense World
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World
Orange County Bancorp, Inc. (NASDAQ: OBT) Distributes Investor Presentation and Financial Disclosure - Defense World
Digital Brands Group (NASDAQ: DBGI) Announces Strategic Partnership with VaynerCommerce - Defense World
MRC Global Inc. Enters into Fifth Amended and Restated Loan Agreement - Defense World
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Advance Auto Parts Enters Amendment to Credit Agreement - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Tetra Tech Reports Record Fiscal 2024 and Fourth Quarter ResultsOn November 13, 2024, Tetra Tech, Inc. (NASDAQ: TTEK) released its financial results for the fourth fiscal quarter and the fiscal year ended September 29, 2024. According to the report - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
Flutter Entertainment Announces Launch of Share Repurchase Program - Defense World
374Water Inc. Reports Third Quarter 2024 Results and Business Update - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Workhorse Group Reschedules Earnings Call to November 19, 2024 - Defense World
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MyChesCo
Passage Bio stock hits 52-week low at $0.54 amid market challenges - Investing.com India
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results - MSN
Vestal Point Capital, LP Increases Stake in Passage Bio Inc - GuruFocus.com
Passage Bio Achieves Milestones in Gene Therapy Trials - Yahoo Finance
Passage Bio Shows Progress in Gene Therapy Trials - TipRanks
PASGPassage Bio, Inc. Latest Stock News & Market Updates - StockTitan
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio's Q3 Shows Progress: Clinical Trial Advances, Cash Runway Extended to 2026 | PASG Stock News - StockTitan
Passage Bio Inc (PASG) 財務データ
収益
当期純利益
現金流量
EPS
Passage Bio Inc (PASG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Dec 10 '24 |
Sale |
0.80 |
8,015 |
6,412 |
7,635,270 |
| ORBIMED ADVISORS LLC | 10% Owner |
Dec 11 '24 |
Sale |
0.80 |
80 |
64 |
7,635,190 |
| ORBIMED ADVISORS LLC | 10% Owner |
Dec 04 '24 |
Sale |
0.79 |
76,200 |
60,198 |
7,718,369 |
| ORBIMED ADVISORS LLC | 10% Owner |
Dec 06 '24 |
Sale |
0.82 |
20,903 |
17,140 |
7,697,466 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):